$NVDA NEWS Nvidia's slide continues as stock tumbles over 10% from recent record Dusseldorf - Delayed Quote • EUR The New Meat Company AG (9AUA.DU) Follow Compare 0.1000 0.0000 (0.00%) As of 8:42:16 AM GMT+1. Market Open. Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 9AUA.DU 1D 5D 0.00% 1M 9.89% 6M 300.00% YTD -87.50% 1Y -88.89% 5Y -98.68% All -98.95% Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Related News View More All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Nvidia Partners With Verizon to Build Scalable AI-Driven Private 5G Platform China Tightens Grip: Nvidia's Mellanox Deal Under Review, Synopsys-Ansys Delayed Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's SolarEdge Poised For Growth Amid Cost Cuts, While Canadian Solar Faces US Policy Headwinds: Goldman Sachs Verizon Teams Up With Nvidia To Power AI Apps Over Private 5G Networks Magnificent Seven Stocks: Nvidia Stock Slashes Losses; Tesla Rallies To New Highs The Dow drops 245 points as it heads for its longest losing streak in decades British borrowing costs surge after wage shock Nvidia-Backed Databricks Raises $10 Bil. Next Hot AI Stock? These Stocks Are Moving the Most Today: Nvidia, Tesla, Broadcom, Pfizer, EVgo, Teva, SolarEdge, Amentum, and More Pfizer's 2025 Outlook: Is This the Breakthrough Investors Have Been Waiting For?